Samantha is a renowned world leader in international drug development for patients with an array of neurological diseases, including a substantial background in Alzheimer’s disease, and she brings extensive experience in clinical development, translational medicine, and global regulatory experience.
Samantha currently serves as the Group Chief Medical Officer of Enigma Biomedical Group where she oversees the development of therapeutic solutions to combat neurodegenerative diseases. Samantha recently held the position of Senior Vice President and Head of Neurodegeneration at Biogen, where she led and co-led the development of two revolutionary drugs, ADUHELM and LEQEMBI, both of which were approved by the FDA for the treatment of Alzheimer’s disease.
Prior to this, Samantha worked at AstraZeneca and held senior roles across research and development in the US, Canada, and Sweden. Samantha currently sits on the board of The Boston Home, a not-for-profit nursing care facility for adults with progressive neurological diseases and Vigil Neuroscience (NASDQ: VIGL) a clinical-stage biotechnology company focused on neurodegenerative diseases.
Subscribe to our newsletters
Sign up for Regulatory News updates: click here
